
    
      JNJ-70218902, the investigational drug, has been shown in pre-clinical studies to work by
      attaching to cancer cells and activating immune cells to kill these cancer cells.This study
      will be conducted in 2 parts: dose escalation (Part 1) and dose expansion (Part 2) and will
      enroll adult men with Metastatic Castration-Resistant Prostate Cancer (MCRPC). Study
      evaluations will include safety, pharmacokinetics, biomarkers and immunogenicity evaluations.
      This study is divided into 3 periods: screening, treatment and post-treatment. The total
      duration of the study will be 2.5 years approximately.
    
  